{"id":"glycopyrrolate-formoterol","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1201335","moleculeType":"Small molecule","molecularWeight":"318.44"},"_dailymed":{"setId":"ae02436e-9528-490e-a844-0c0f6f2843f9","title":"BEVESPI AEROSPHERE (GLYCOPYRROLATE AND FORMOTEROL FUMARATE) AEROSOL, METERED [ASTRAZENECA PHARMACEUTICALS LP]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets two pathways in obstructive airway disease: glycopyrrolate antagonizes acetylcholine at M3 muscarinic receptors on airway smooth muscle and mucus glands, reducing secretions and bronchoconstriction, while formoterol activates beta-2 adrenergic receptors to promote smooth muscle relaxation and bronchodilation. Together, they provide complementary bronchodilatory and secretion-reducing effects for maintenance therapy in chronic obstructive pulmonary disease (COPD).","oneSentence":"Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:08:31.401Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07489911","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","status":"RECRUITING","sponsor":"Chiesi Slovenija, d.o.o.","startDate":"2024-11-04","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":200},{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT06786767","phase":"","title":"Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting","status":"COMPLETED","sponsor":"Chiesi Bulgaria","startDate":"2025-02-01","conditions":"Asthma, Asthma Patients, Asthma Bronchiale","enrollment":281},{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT05862545","phase":"","title":"Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":250},{"nctId":"NCT07069829","phase":"","title":"Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1400},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT04320342","phase":"PHASE3","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-04-28","conditions":"COPD, COPD Exacerbation","enrollment":3433},{"nctId":"NCT06368427","phase":"","title":"Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-30","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":10},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT03081156","phase":"PHASE4","title":"The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD","status":"COMPLETED","sponsor":"William Stringer, md","startDate":"2017-03-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":52},{"nctId":"NCT06075095","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-11","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":297},{"nctId":"NCT06744374","phase":"","title":"A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22369},{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT04937543","phase":"PHASE2","title":"Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2021-06-28","conditions":"Covid19","enrollment":50},{"nctId":"NCT06844175","phase":"","title":"Early Screening of Young COPD and Pre-COPD","status":"NOT_YET_RECRUITING","sponsor":"yanmengkang","startDate":"2025-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1252},{"nctId":"NCT06514144","phase":"","title":"Exacerbations Among Patients Receiving Breztri (EROS Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-01","conditions":"Pulmonary Disease, Chronic Obstructive, Retrospective Studies","enrollment":2409},{"nctId":"NCT06678191","phase":"","title":"Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2024-10-24","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale","enrollment":800},{"nctId":"NCT05830071","phase":"PHASE1","title":"A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-03-29","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":95},{"nctId":"NCT04536402","phase":"","title":"Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3520},{"nctId":"NCT06317428","phase":"","title":"NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.","status":"RECRUITING","sponsor":"Istituto Nazionale di Ricovero e Cura per Anziani","startDate":"2022-06-28","conditions":"COPD","enrollment":29},{"nctId":"NCT05948891","phase":"","title":"Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study","status":"RECRUITING","sponsor":"Chiesi SAS","startDate":"2023-08-01","conditions":"COPD","enrollment":500},{"nctId":"NCT05970263","phase":"PHASE4","title":"IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-01-19","conditions":"COPD","enrollment":""},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT04671355","phase":"PHASE4","title":"TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","status":"WITHDRAWN","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-04","conditions":"COPD","enrollment":""},{"nctId":"NCT03627858","phase":"","title":"Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting","status":"COMPLETED","sponsor":"Chiesi SA/NV","startDate":"2018-08-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":149},{"nctId":"NCT02119234","phase":"PHASE1","title":"Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"COPD","enrollment":36},{"nctId":"NCT01917331","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1368},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT02040597","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":42},{"nctId":"NCT01398111","phase":"PHASE1","title":"Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-05","conditions":"COPD","enrollment":44},{"nctId":"NCT01476813","phase":"PHASE2","title":"Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":281},{"nctId":"NCT02127866","phase":"PHASE2","title":"Triple in Asthma Dose Finding","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-04","conditions":"Asthma","enrollment":211},{"nctId":"NCT04737655","phase":"PHASE4","title":"Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care","status":"UNKNOWN","sponsor":"PARZIBUT Gilles","startDate":"2021-02-15","conditions":"COPD Exacerbation","enrollment":200},{"nctId":"NCT03250182","phase":"PHASE1","title":"A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-08-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":30},{"nctId":"NCT03075267","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-04-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":96},{"nctId":"NCT03324607","phase":"PHASE2, PHASE3","title":"Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI","status":"COMPLETED","sponsor":"Bastiaan Driehuys","startDate":"2018-04-20","conditions":"COPD","enrollment":20},{"nctId":"NCT03162055","phase":"PHASE3","title":"Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":1119},{"nctId":"NCT02343458","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-03-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1756},{"nctId":"NCT03740373","phase":"PHASE1","title":"A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-09-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10},{"nctId":"NCT02347085","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":43},{"nctId":"NCT02189304","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 in Healthy Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-06-01","conditions":"COPD","enrollment":59},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02196714","phase":"PHASE1","title":"PK Study of PT003 and PT001 in Japanese Healthy Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-07","conditions":"COPD","enrollment":24},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT01854658","phase":"PHASE3","title":"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1615},{"nctId":"NCT02268396","phase":"PHASE3","title":"Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-11","conditions":"COPD","enrollment":138},{"nctId":"NCT02693769","phase":"PHASE2, PHASE3","title":"A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils","status":"TERMINATED","sponsor":"Mundipharma Research Limited","startDate":"2016-07","conditions":"ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)","enrollment":2},{"nctId":"NCT01587079","phase":"PHASE2","title":"Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":159},{"nctId":"NCT02197975","phase":"PHASE1","title":"Randomized, Crossover Safety and Pharmacokinetics Study of PT010","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-08","conditions":"COPD","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":88,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}